高危肝母细胞瘤向癌的异步转化
该研究通过单核RNA/DNA测序及多区域纵向测序,揭示具有癌特征的肝母细胞瘤(HBC)由HB样、HBC样和HCC样细胞异质性混合组成,HBC细胞因WNT信号异常激活而阻滞于早期肝干细胞阶段,导致化疗耐药且预后差于HB,抑制WNT信号可促进分化并增强化疗敏感性。
要点
- HBC由HB样、HBC样和HCC样细胞异质性混合组成,非单一杂交细胞。
- HBC细胞起源于WNT信号异常激活致早期肝干细胞分化阻滞的HB前体。
- 抑制WNT信号可促进HBC分化并增强化疗敏感性。
核心结论
- HBCs comprise heterogeneous mixtures of HB-like, HBC-like, and HCC-like molecular cell types.
- HBC cells originate from HB cells arrested at early hepatic stem cell development stages due to aberrant WNT signaling activation.
- Inhibition of WNT signaling promoted differentiation and enhanced sensitivity to chemotherapy.
研究设计与样本
- 多组学分析:单核RNA测序、单核DNA测序及多区域纵向bulk RNA和DNA测序。
- 三分之二的样本为化疗后切除标本。
主要发现
- HBCs comprise heterogeneous mixtures of HB-like, HBC-like, and HCC-like molecular cell types.
- Outcomes in HBC are significantly worse than in HB.
- HBC cells are more chemoresistant than HB cells, with resistance shaped by their cell identity, genetic alterations, and embryonic differentiation stage.
- Each analyzed HBC reflected a dynamic process of multiple HB-to-HBC and HBC-to-HCC transitions.
关键数值与推荐
- HBCs comprise heterogeneous mixtures of HB-like, HBC-like, and HCC-like molecular cell types.
- HBC cells originate from HB cells arrested at early hepatic stem cell development stages because of aberrant WNT signaling activation.
- Inhibition of WNT signaling promoted differentiation and enhanced sensitivity to chemotherapy.
临床怎么用
- HBCs应被视为异质性混合细胞群体,其预后显著差于HB且化疗耐药更强。
- WNT信号抑制联合化疗可能是促进HBC分化并增敏的潜在治疗策略。
局限性
- A limitation of our study is our inability to pinpoint the role of chemotherapy-induced genome modifications.
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Most pediatric hepatocellular tumors are classified as hepatoblastoma (HB) or hepatocellular carcinoma (HCC), yet a subset exhibits mixed histological and molecular features. These hepatoblastomas with carcinoma features (HBCs) include cases provisionally designated as hepatocellular neoplasm-not otherwise specified (HCN-NOS). Their biology remains poorly understood, with unresolved questions about their cellular composition and outcomes. It is unclear whether HBCs comprise hybrid cells with combined HB and HCC characteristics (HBC cells) or admixtures of distinct HB and HCC cells. We characterized the biology, etiology, cellular composition, and evolutionary dynamics of HBCs. METHODS: We performed multi-omics profiling - including single-nucleus RNA sequencing, single-nucleus DNA sequencing, and multi-region longitudinal bulk RNA and DNA sequencing - to characterize HBC composition, evolution, and treatment response. Two-thirds of our samples were post-chemotherapy resections. RESULTS: HBCs comprise heterogeneous mixtures of HB-like, HBC-like, and HCC-like molecular cell types. Outcomes in HBC are significantly worse than in HB, and HBC cells are more chemoresistant than HB cells, with resistance shaped by their cell identity, genetic alterations, and embryonic differentiation stage. HBC cells originate from HB cells that were arrested at early hepatic stem cell development stages because of aberrant WNT signaling activation. Inhibition of WNT signaling promoted differentiation and enhanced sensitivity to chemotherapy. Furthermore, each analyzed HBC reflected a dynamic process of multiple HB-to-HBC and HBC-to-HCC transitions, underscoring their evolutionary complexity. A limitation of our study is our inability to pinpoint the role of chemotherapy-induced genome modifications. CONCLUSIONS: Multi-omics profiling of HBCs revealed key insights into their biology and composition, demonstrating that they originate from HB precursors at early hepatic stem cell development stages and that their differentiation arrest depends on sustained aberrant WNT signaling activity. IMPACT AND IMPLICATIONS: Hepatoblastomas with carcinoma features (HBCs) represent a poorly understood subset of pediatric liver tumors with mixed characteristics of hepatoblastoma (HB) and hepatocellular carcinoma (HCC). Using multi-omics profiling, we show that HBCs comprise heterogeneous mixtures of HB-like, intermediate HBC-like, and HCC-like cell populations that arise from HB precursors arrested at early hepatic stem cell developmental stages due to aberrant WNT signaling. This differentiation arrest contributes to chemoresistance and poorer clinical outcomes compared with HB. Importantly, pharmacologic inhibition of WNT signaling promoted differentiation and increased chemotherapy sensitivity, suggesting a potential therapeutic strategy. These findings refine the biological classification of HBCs and highlight differentiation-based treatment approaches for this aggressive tumor subtype.
引用
- Yu X, Sarabia S, Urbicain M, et al. Asynchronous transitions from high-risk hepatoblastoma to carcinoma. J Hepatol. 2026. PMID: 41771380. doi:10.1016/j.jhep.2026.02.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。